Agent for alleviating menstrual symptoms and use thereof

Abstract

To provide an agent for alleviating menstrual symptoms whose alleviating effect is improved; a stick-shaped agent for alleviating menstrual symptoms, comprising the agent for alleviating menstrual symptoms; and a method for alleviating menstrual symptoms using the agent for alleviating menstrual symptoms.SOLUTION: An agent for alleviating menstrual symptoms of the present invention contains one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, and α-pinene. In one example, a stick-shaped agent for alleviating menstrual symptoms 21 includes a case 23 and an oily solid 22 housed in the case 23, and the oily solid 22 contains the agent for alleviating menstrual symptoms.SELECTED DRAWING: Figure 1

Description

Technical Field

[0001] The present invention relates to a menstrual symptom reliever and its use.

Background Art

[0002] As menstrual associated symptoms, premenstrual syndrome (PMS) and dysmenorrhea, which are related to physical and mental discomfort before and during menstruation, are known. PMS is a symptom that occurs periodically from 3 to 10 days before menstruation and refers to a group of mental and physical symptoms that disappear after the start of menstruation. Examples of such symptoms include irritability, aggressiveness, depression, decreased concentration, lower abdominal pain, low back pain, breast swelling, breast pain, headache and other symptoms. Although there are individual differences in the degree of these symptoms, when the symptoms are severe, they may interfere with work and daily life, or deteriorate human relationships at home and in the workplace.

[0003] Dysmenorrhea is generally referred to as a symptom during menstruation accompanied by abnormally strong pain or systemic disorders. When dysmenorrhea occurs, it may be necessary to stay in bed or make work difficult. Dysmenorrhea is also called menstrual pain. Representative symptoms of dysmenorrhea include pain such as lower abdominal pain and low back pain, and various physical symptoms such as nausea, vomiting, diarrhea, headache and the like. Among gynecological diseases, the frequency of medical consultations is relatively high. Among the increasing opportunities for women's social advancement, some scholars have pointed out the relationship between women's labor productivity and PMS. The alleviation and reduction of menstrual-related symptoms represented by PMS and dysmenorrhea are also important social issues for improving women's QOL (Quality of Life).

[0004] Some menstrual symptom relievers have been proposed. For example, in Patent Documents 1, 2, and 3, symptom relievers containing pharmaceutical ingredients have been proposed respectively. However, in the use of pharmaceutical ingredients, their side effects are a concern. Therefore, some menstrual symptom relievers containing specific oils and fragrances have been proposed (Patent Documents 4, 5, and 6).

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Patent Document 5

Patent Document 6

Summary of the Invention

Problems to be Solved by the Invention

[0006] However, according to the studies by the present inventors, in conventional menstrual symptom relievers, there is room for improvement in the effect of relieving menstrual symptoms. Also, conventional menstrual symptom relievers cannot be easily used. Therefore, it is difficult to say that the menstrual symptom relievers themselves are widely popular.

[0007] The present invention provides a menstrual symptom reliever with an improved effect of relieving menstrual symptoms, a stick-shaped menstrual symptom reliever provided with the menstrual symptom reliever, and a method for relieving menstrual symptoms using the menstrual symptom reliever.

Means for Solving the Problems

[0008] As a result of intensive studies, the present inventors have found that an improved effect of relieving menstrual symptoms can be expected from the squeezed liquid, extract, or distillate obtained from the xylem of trees or the leaves of trees, and have thus completed the present invention.

[0009] The present invention has the following aspects. [1] A menstrual symptom reliever containing one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, and α-pinene. [2] A menstrual symptom reliever containing one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimethol, nerolidol, camphor, α-isomethylionone, β-pinene, bornyl acetate, β-farnesene, camphene, geraniol, citronellol, nerol, geranial, neral, and γ-terpinene. [3] A menstrual symptom reliever containing one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimethol, nerolidol, borneol, camphor, α-isomethylionone, 3-pentyltetrahydro-2H-pyran-4-yl acetate, β-pinene, bornyl acetate, β-farnesene, camphene, geraniol, citronellol, nerol, geranial, neral, γ-terpinene, ethylenebrassylate, dihydromyrcenol, 3-methyl-5-phenylpentan-1-ol, 6,6-dimethoxy-2,5,5-trimethyl-2-hexene, citronellyl nitrile, benzyl alcohol, α-terpineol, γ-undecalactone, myrcene, geranyl acetate, γ-terpineol, and methylheptenone. [4] A menstrual symptom reliever containing one or more selected from the group consisting of lavender-like fragrances, verbena-like fragrances, and mint verbena-like fragrances as active ingredients. [5] The menstrual symptom reliever according to [4], wherein the lavender-like fragrance contains linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimethol, nerolidol, borneol, camphor, bornyl acetate, 3-pentyltetrahydro-2H-pyran-4-yl acetate, β-farnesene, β-pinene, camphene, and α-isomethylionone. [6] The menstrual symptom reliever according to [4] or [5], wherein the verbena-like fragrance contains hexyl cinnamic aldehyde, limonene, linalool, geraniol, citronellol, nerol, linalyl acetate, geranial, neral, citronellyl nitrile, benzyl alcohol, α-terpineol, β-pinene, γ-undecalactone, myrcene, γ-terpinene, geranyl acetate, γ-terpineol, methyl heptenone, α-pinene, β-farnesene, bornyl acetate, and camphene. [7] The menstrual symptom reliever according to any one of [4] to [6], wherein the mint verbena-like fragrance contains hexyl cinnamic aldehyde, ethylene brassylate, tetrahydro-2-isobutyl-4-methylpyran-4-ol, linalool, limonene, dihydromyrcenol, geraniol, linalyl acetate, citronellol, nerol, geranial, β-pinene, galaxolide, β-farnesene, neral, 3-methyl-5-phenylpentan-1-ol, bornyl acetate, camphene, α-pinene, 6,6-dimethoxy-2,5,5-trimethyl-2-hexene, and γ-terpinene. [8] The menstrual symptom reliever according to any one of [1] to [7], which is used for premenstrual symptoms. A menstrual symptom reliever according to any one of [1] to [8], which is used for symptoms during menstruation. A menstrual symptom reliever according to any one of [1] to [9], which is used for the purpose of relieving at least one of physical symptoms and mental symptoms. The menstrual symptom reliever according to

[10] , wherein the physical symptom includes at least one symptom selected from the group consisting of abnormal appetite, abnormal sleep, breast pain, breast fullness, a feeling of swelling, weight gain, headache, arthralgia, and myalgia. The menstrual symptom reliever according to

[10] or

[11] , wherein the mental symptom includes at least one symptom selected from the group consisting of depression, anxiety, emotional instability, anger, fatigue, decreased concentration, and a feeling of being overwhelmed.

[13] A case, An oily solid agent contained in the case, and comprising A stick-shaped menstrual symptom reliever, wherein the oily solid agent contains a menstrual symptom reliever according to any one of [1] to

[12] .

[14] A container, An aromatic agent contained in the container, and comprising An aromatic agent-type menstrual symptom reliever, wherein the aromatic agent contains a menstrual symptom reliever according to any one of [1] to

[12] .

[15] A container, A bath agent contained in the container, and comprising A bath agent-type menstrual symptom reliever, wherein the bath agent contains a menstrual symptom reliever according to any one of [1] to

[12] .

[16] A method for relieving menstrual symptoms, which includes volatilizing a menstrual symptom reliever according to any one of [1] to

[12] .

[17] A method for relieving menstrual symptoms, which includes inhaling a menstrual symptom reliever according to any one of [1] to

[12] .

[18] A method for relieving menstrual symptoms, A method for alleviating menstrual symptoms, which comprises continuously using a menstrual symptom reliever described in any one of [1] to

[12] from 10 days before the start of menstruation until during menstruation.

[19] A method for alleviating menstrual symptoms, which comprises continuously using a menstrual symptom reliever described in any one of [1] to

[12] from 5 days before the start of menstruation until during menstruation.

[20] A method for alleviating menstrual symptoms, which comprises using a menstrual symptom reliever described in any one of [1] to

[12] when symptoms occur during menstruation.

[21] Step 1 of obtaining evaluation (1) regarding menstrual symptoms before menstruation, without the subject smelling a menstrual symptom reliever described in any one of [1] to

[12] ; Step 2 of obtaining evaluation (2) regarding menstrual symptoms after menstruation, without the subject smelling a menstrual symptom reliever described in any one of [1] to

[12] ; Step 3 of the subject smelling a menstrual symptom reliever described in any one of [1] to

[12] before menstruation and obtaining evaluation (3) regarding menstrual symptoms; Step 4 of discriminating the presence or absence of the onset of premenstrual syndrome by comparing the evaluation (1) obtained in Step 1 with the evaluation (2) obtained in Step 2; Step 5 of comparing the evaluation (1) and the evaluation (3) obtained from the subject in whom the onset of premenstrual syndrome was recognized in Step 4; An evaluation method for the effect of alleviating menstrual symptoms, which has the above steps.

[22] The evaluation method according to

[21] , wherein in each of Step 1, Step 2, Step 3, Step 4 and Step 5, an evaluation is obtained before the start of menstruation or on at least the first day or more since the start of menstruation.

[23] A first output unit that outputs at least one question regarding menstrual symptoms from a certain period after the previous menstruation until the next menstruation; for the question, a first acquisition unit that obtains an answer before menstruation without smelling the menstrual symptom reliever described in any of [1] to

[12] ; a second output unit that outputs at least one question regarding menstrual symptoms from a certain period after the start of menstruation until a certain period; for the question, a second acquisition unit that obtains an answer after menstruation without smelling the menstrual symptom reliever described in any of [1] to

[12] ; a third output unit that outputs at least one question regarding menstrual symptoms from a certain period after the previous menstruation until the next menstruation; for the question, a third acquisition unit that smells the menstrual symptom reliever described in any of [1] to

[12] and obtains an answer before menstruation; a first determination unit that determines the presence or absence of the onset of premenstrual syndrome by comparing the answer of the first acquisition unit and the answer of the second acquisition unit; a second determination unit that determines the improvement of menstrual symptoms by the menstrual symptom reliever by comparing the answers of the first acquisition unit and the third acquisition unit obtained from a subject in whom the onset of premenstrual syndrome has been recognized by the first determination unit; and an output unit that outputs the result determined by the second determination unit. A menstrual symptom improvement determination system.

Effect of the Invention

[0010] According to the present invention, it is possible to provide a menstrual symptom reliever with an improved menstrual symptom relief effect, a stick-shaped menstrual symptom reliever including the menstrual symptom reliever, and a menstrual symptom relief method using the menstrual symptom reliever.

Brief Description of the Drawings

[0011]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Figure 12

Figure 13

Figure 14

Figure 15

Figure 16

Figure 17

Mode for Carrying Out the Invention

[0012] In this specification, the numerical range represented by "~" means a range including the numerical values described before and after "~" as the lower limit value and the upper limit value. For example, "A~B%" means A% or more and B% or less.

[0013] Some representative embodiments of the menstrual symptom reliever will be described below. The following description relates to representative examples of the embodiments, and the embodiments of the present invention are not limited to the following description.

[0014] The menstrual symptom reliever according to one aspect contains one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, and α-pinene.

[0015] The menstrual symptom reliever according to another aspect contains one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimethol, nerolidol, borneol, camphor, α-isomethyl ionone, β-pinene, bornyl acetate, β-farnesene, camphene, geraniol, citronellol, nerol, geranial, neral, and γ-terpinene.

[0016] Menstrual symptom relievers according to yet another aspect contain one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimethol, nerolidol, borneol, camphor, α-isomethyl ionone, 3-pentyltetrahydro-2H-pyran-4-yl acetate, β-pinene, bornyl acetate, β-farnesene, camphene, geraniol, citronellol, nerol, geranial, neral, γ-terpinene, ethylene brassylate, dihydromyrcenol, 3-methyl-5-phenylpentan-1-ol, 6,6-dimethoxy-2,5,5-trimethyl-2-hexene, citronellyl nitrile, benzyl alcohol, α-terpineol, γ-undecalactone, myrcene, geranyl acetate, γ-terpineol and methyl heptenone.

[0017] Menstrual symptom relievers according to yet another aspect contain one or more selected from the group consisting of lavender-like fragrances, verbena-like fragrances and mint verbena-like fragrances as active ingredients.

[0018] The lavender-like fragrance preferably contains linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimethol, nerolidol, borneol, camphor, bornyl acetate, 3-pentyltetrahydro-2H-pyran-4-yl acetate, β-farnesene, β-pinene, camphene and α-isomethyl ionone.

[0019] As the verbena-like fragrance, it is preferably contained hexyl cinnamic aldehyde, limonene, linalool, geraniol, citronellol, nerol, linalyl acetate, geranial, neral, citronellyl nitrile, benzyl alcohol, α-terpineol, β-pinene, γ-undecalactone, myrcene, γ-terpinene, geranyl acetate, γ-terpineol, methyl heptenone, α-pinene, citronellyl formate and sabinene.

[0020] As the mint verbena-like fragrance, it is preferably contained hexyl cinnamic aldehyde, ethylene brassylate, tetrahydro-2-isobutyl-4-methylpyran-4-ol, linalool, limonene, dihydromyrcenol, geraniol, linalyl acetate, citronellol, nerol, geranial, β-pinene, galaxolide, β-farnesene, neral, 3-methyl-5-phenylpentan-1-ol, bornyl acetate, camphene, α-pinene, 6,6-dimethoxy-2,5,5-trimethyl-2-hexene and γ-terpinene.

[0021] Each component may be used as it is, may be further concentrated, purified or blended with a suitable solvent as required. For example, solvents such as water, ethanol, isopropyl alcohol, propyl alcohol, propylene glycol, ethylene glycol, ethylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene alcohol monoethyl ether, 3-methoxy-3-methyl-1-butanol can be used. By blending with a solvent so that the concentration of the active ingredient amount is about 0.01 to 99% by mass, a menstrual symptom reliever can be prepared.

[0022] [Use] According to the menstrual symptom reliever of the present invention, various symptoms related to menstruation can be relieved. The menstrual symptom reliever may be used for the purpose of relieving premenstrual symptoms, may be used for the purpose of relieving symptoms during menstruation, or may be used both before and during menstruation. The symptoms may be physical symptoms, mental symptoms, or both physical and mental symptoms.

[0023] Examples of physical symptoms include abnormal appetite, abnormal sleep, breast pain, breast fullness, a feeling of swelling, weight gain, headache, joint pain, and muscle pain. Examples of mental symptoms include depression, anxiety, mood instability, anger, listlessness, decreased concentration, and a feeling of being overwhelmed. However, menstrual symptoms are not limited to these examples.

[0024] The menstrual symptom reliever can be used for the purpose of reducing symptoms related to menstruation by applying it to fragrances, foods, cosmetics, quasi-drugs, pharmaceuticals, and daily necessities. Also, it can be used for the same purpose by applying the menstrual symptom reliever to the living space or articles.

[0025] For example, by blending a menstrual symptom reliever into common food ingredients, a food containing the menstrual symptom reliever can be produced. Beverage forms such as drinks, candies, troches, chewing gums, etc. are preferred as the food.

[0026] Examples of cosmetics containing the menstrual symptom reliever include soaps, shampoos, bath salts, perfumes, eau de parfum, colognes, creams, lotions, body lotions, body powders, body creams, hand creams, body washes, massage oils, hair creams, hair lotions, and hair sprays. The perfume may be a spray perfume or a roll-on perfume and is not particularly limited.

[0027] For example, by using a pharmaceutically acceptable carrier according to a conventional method, the menstrual symptom reliever can be formulated into various forms to produce pharmaceuticals or quasi-drugs. Forms of pharmaceuticals or quasi-drugs include, for example, tablets, powders, capsules, syrups, solutions, sublingual tablets, troches, mouthwashes, oral cooling agents, gargles, nasal drops, sprays, throat sprays, dentifrices, and dispersants, but are not limited thereto. The dosage of the pharmaceutical can be appropriately set according to the administration purpose, the age of the patient, and the symptoms.

[0028] Daily necessities containing the menstrual symptom reliever are not particularly limited, and examples include dispersants, fragrances, deodorants, fragrance deodorants, and additives to the water of humidifiers. In addition, fiber products impregnated with the menstrual symptom reliever are also included. Examples of fiber products include masks, gauze, bandages, towels, handkerchiefs, towels, tissues, wet tissues, gloves, underwear, white coats, surgical gowns, diapers, sanitary products, bedding (futons, pillows, sheets, pillowcases, nightgowns), and pillow mists.

[0029] In addition to the above-mentioned components, other fragrances may be further blended in the menstrual symptom reliever. For example, other fragrances include, for example, animal fragrances such as musk, civet, and ambergris, and plant fragrances such as abies oil, action oil, almond oil, angelica root oil, pageil oil, bergamot oil, perch oil, boabarrow oil, kaya buti oil, gananga oil, capsicum oil, caraway oil, cardamom oil, cassia oil, celery oil, cinnamon oil, citronella oil, cognac oil, coriander oil, cumin oil, camphor oil, basil oil, estogolan oil, eucalyptus oil, fennel oil, garlic oil, ginger oil, grapefruit oil, hop oil, lemon oil, lemongrass oil, nutmeg oil, mandarin oil, hokka oil, orange oil, sage oil, star anise oil, terpine oil, rosemary oil, eucalyptus oil, anise oil, lavender oil, cumin oil, cinnamon oil, hiba oil, etc.

[0030] In addition, as other fragrances, artificial fragrances such as synthetic fragrances or extracted fragrances can also be used. For example, alcohol-based fragrances such as ethyl linalool, anis alcohol, and β-phenethyl alcohol, phenolic fragrances such as eugenol, aldehyde-based fragrances such as n-butyl aldehyde, isobutyl aldehyde, hexyl aldehyde, citral, citronellal, and benzaldehyde, ketone-based fragrances such as carvone, menthone, camphor, and acetophenone, lactone-based fragrances such as γ-butyrolactone and cineole, ester-based fragrances such as octyl acetate, cinnamyl acetate, butyl propionate, and methyl benzoate, etc. Surfactants and hydrotropes may be used as necessary.

[0031] As other fragrances, artificial fragrances such as synthetic fragrances and extracted fragrances can also be used. For example, hydrocarbon-based fragrances such as α-farnesene, alcohol-based fragrances such as ethyl linalool, anis alcohol, and β-phenethyl alcohol, phenolic fragrances such as eugenol, aldehyde-based fragrances such as n-butyl aldehyde, isobutyl aldehyde, hexyl aldehyde, citral, citronellal, and benzaldehyde, ketone-based fragrances such as carvone, menthone, camphor, acetophenone, and ionone, lactone-based fragrances such as γ-butyrolactone and cineole, ester-based fragrances such as octyl acetate, cinnamyl acetate, butyl propionate, and methyl benzoate. Surfactants and hydrotropes may be used as necessary.

[0032] [Usage Method] In one example, a method for relieving menstrual symptoms includes volatilizing a menstrual symptom reliever. By volatilizing the menstrual symptom reliever in the space, the active ingredient of the menstrual symptom reliever can be inhaled, so that the effect of relieving menstrual symptoms can be obtained. In another example, a method for relieving menstrual symptoms includes inhaling a menstrual symptom reliever.

[0033] For example, a spraying agent, a fragrance, a deodorant, an aromatic deodorant, etc. may be volatilized or sprayed into the air for use. It is an advantage that the effect of relieving menstrual symptoms can be imparted to the daily living space. The volatilization method and spraying method are not particularly limited. Examples include a method of directly volatilizing the menstrual symptom reliever, a method of volatilizing it using a volatilizer, a method using an atomizer such as a pump spray, an aerosol, an ultrasonic vibrator, a pressurized liquid spray, or a pressurized air atomizing spray device. The menstrual symptom reliever may be volatilized using a diffuser.

[0034] The amount of the active ingredient during use may be appropriately changed depending on the administration purpose and dosage form. Any amount that can sufficiently achieve the effect of relieving discomfort symptoms by inhalation is acceptable. For example, in the case of an indoor fragrance, the active ingredient is preferably 0.05 to 20% by mass. As for the concentration of the volatilized component, 1 to 4000 μg / m 3 is preferable, 10 to 2000 μg / m 3 is more preferable, and 20 to 1000 μg / m 3 is even more preferable.

[0035] In one example, the method for relieving menstrual symptoms includes continuously using the menstrual symptom reliever from 10 days before the start of menstruation until the end of menstruation. In another example, the method for relieving menstrual symptoms includes continuously using the menstrual symptom reliever from 5 days before the start of menstruation until the end of menstruation. In yet another example, the method for relieving menstrual symptoms includes using the menstrual symptom reliever when symptoms occur during menstruation.

[0036] [Stick-shaped menstrual symptom reliever] The stick-shaped menstrual symptom reliever includes a case and an oily solid agent housed in the case. The oily solid agent contains the menstrual symptom reliever.

[0037] In one example, the oily solid agent further contains various waxes in addition to the menstrual symptom reliever. Examples of the wax include synthetic wax, polyethylene, neopentyl glycol dicaprate, methyl polymethacrylate, isopropyl myristate, triethylhexanoin, and dimethicone.

[0038] The oily solid agent may further contain other components such as fragrances and fillers as needed. Examples of the fragrances include the same fragrances as those described above. The filler may be an inorganic filler or an organic filler, and is not particularly limited.

[0039] The case of the stick-shaped menstrual symptom reliever is not particularly limited as long as it can accommodate the oily solid agent, and a cylindrical case is mentioned. The cross-sectional shape of the case is also not particularly limited and can be arbitrarily set according to the shape of the oily solid agent. The case may be able to feed out the oily solid agent during use, and may be provided with a cap for protecting the oily solid agent when not in use.

[0040] Fig. 1 shows an example of a stick-shaped menstrual symptom reliever. The stick-shaped menstrual symptom reliever 21 shown in Fig. 1 includes a case 23 and an oily solid agent 22 housed in the case 23. The oily solid agent 22 contains a menstrual symptom reliever. When using the stick-shaped menstrual symptom reliever 21, as shown in Fig. 1, the oily solid agent 22 is fed out above the opening surface of the case 23. Thereafter, by directly inhaling the fragrance, inhaling the fragrance volatilized from the oily solid agent 22 applied to the wrist or the like, or inhaling the fragrance when breathing through the oily solid agent 22 applied to a mask or the like, a menstrual symptom relief effect can be obtained. After use, the oily solid agent 22 may be stored below the opening surface of the case 23, or may be covered with a cap (not shown).

[0041] [Aromatherapy-Type Menstrual Symptom Reliever] The aromatherapy-type menstrual symptom reliever includes a container and an aromatherapy agent housed in the container. The aromatherapy agent contains a menstrual symptom reliever.

[0042] In one example, the fragrance agent may further contain various solvents and surfactants in addition to the menstrual symptom reliever. Examples of the solvent include water, ethanol, isopropyl alcohol, propyl alcohol, propylene glycol, ethylene glycol, ethylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene alcohol monoethyl ether, and 3-methoxy-3-methyl-1-butanol. As the surfactant, various nonionic surfactants, cationic surfactants, anionic surfactants, and amphoteric surfactants can be used.

[0043] The fragrance agent may further contain other components such as fragrances, deodorants, and pigments as needed. Examples of the fragrance include the same fragrances as those described above. The fragrance agent may be in liquid form, gel form, or solid form.

[0044] When using the fragrance agent type menstrual symptom reliever, the menstrual symptom relief effect can be obtained by directly inhaling the volatilized fragrance in a living space or the like after volatilizing it into the space using a suitable diffuser or nebulizer.

[0045] [Bath agent type menstrual symptom reliever] The bath agent type menstrual symptom reliever includes a container and a bath agent stored in the container. The bath agent contains a menstrual symptom reliever. The bath agent may be in powder form, tablet form, or liquid form. The bath agent is put into the bathtub during bathing. The menstrual symptom relief effect can be obtained by inhaling the fragrance volatilized from the hot water.

[0046] In one example, the bath agent contains various components in addition to the menstrual symptom reliever. For example, sodium carbonate, sodium bicarbonate, sodium sulfate, sodium chloride, magnesium sulfate, and titanium oxide can be mentioned. In the case of a liquid bath agent, for example, 1,3-butylene glycol, liquid paraffin, glycerin, ethanol, purified water, and a surfactant can be mentioned.

[0047] The bath agent may further contain other components such as fragrances, humectants, and essential oils as needed. Examples of the fragrance include the same fragrances as those described above.

[0048] [Method for Evaluating the Effect of Alleviating Menstrual Symptoms] In one example, the method for evaluating the effect of alleviating menstrual symptoms includes the following Step 1, Step 2, Step 3, Step 4, and Step 5. · Step 1: A step of obtaining Evaluation (1) regarding menstrual symptoms before menstruation without the subject smelling the menstrual symptom reliever. · Step 2: A step of obtaining Evaluation (2) regarding menstrual symptoms after menstruation without the subject smelling the menstrual symptom reliever. · Step 3: A step of having the subject smell the menstrual symptom reliever before menstruation and obtaining Evaluation (3) regarding menstrual symptoms. · Step 4: A step of determining the presence or absence of the onset of premenstrual syndrome by comparing Evaluation (1) obtained in Step 1 and Evaluation (2) obtained in the said Step 2. · Step 5: A step of comparing Evaluation (1) and Evaluation (3) obtained from the subjects in whom the onset of premenstrual syndrome was recognized in Step 4.

[0049] Regarding Evaluation (1) regarding menstrual symptoms, Evaluation (2) regarding menstrual symptoms, and Evaluation (3) regarding menstrual symptoms, the evaluation items are not particularly limited. Evaluation can be performed respectively from physical symptoms and mental symptoms. For example, as in the examples described later, the Japanese version of DRSP (Dairy Records of Severity of Problems) may be used.

[0050] The method for obtaining Evaluation (1) regarding menstrual symptoms, Evaluation (2) regarding menstrual symptoms, and Evaluation (3) regarding menstrual symptoms is not particularly limited. A smartphone, a personal computer, or a tablet terminal may be used, or it may be obtained by an app or a web questionnaire.

[0051] Regarding the evaluation acquisition period, in each of Step 1, Step 2, Step 3, Step 4, and Step 5, it is preferable to acquire evaluations before the start of menstruation or starting from the start of menstruation for at least the first day or more.

[0052] As the subject, it is preferable to satisfy at least one of the following conditions, and most preferably to satisfy all of them. · Being a woman aged 20 - 45 years old. · Having had menstruation within the last year and having mental symptoms such as being irritated or feeling anxious during the last year. · The degree of symptoms corresponding to either "being extremely troubled, unable to do work, housework, study, etc. at all", "being very troubled", "being somewhat troubled", "not being troubled", or "having no symptoms" among the five levels, and corresponding to either "being very troubled" or "being somewhat troubled". · The menstrual cycle being stable at about 25 - 35 days. · Not being currently pregnant and having no recent pregnancy plan. · Not taking medications or supplements for the purpose of improving premenstrual symptoms. However, taking analgesics is allowed. · Not having been diagnosed with "depression" or "depressive state" from the past to the present. · Not being under treatment in a psychiatric department or psychosomatic medicine department. · Having the intention to use stick-shaped perfume.

[0053] The evaluation comparison method is not particularly limited either. For example, the average values of the evaluation values may be compared, or various other statistical methods may also be used.

[0054] [Menstrual Symptom Improvement Judgment System] For the evaluation of the menstrual symptom alleviation effect, the following menstrual symptom improvement determination system is also useful. According to one aspect of the present invention, a first output unit that outputs at least one question regarding menstrual symptoms at least once from a certain period after the previous menstruation until the next menstruation; for the question, a first acquisition unit that acquires an answer before menstruation without smelling a menstrual symptom reliever; a second output unit that outputs at least one question regarding menstrual symptoms at least once from a certain period after the start of menstruation until a certain period; for the question, a second acquisition unit that acquires an answer after the end of menstruation without smelling a menstrual symptom reliever; a third output unit that outputs at least one question regarding menstrual symptoms at least once from a certain period after the previous menstruation until the next menstruation; for the question, a third acquisition unit that smells a menstrual symptom reliever and acquires an answer before menstruation; a first determination unit that determines the presence or absence of the onset of premenstrual syndrome by comparing the answer of the first acquisition unit and the answer of the second acquisition unit; a second determination unit that determines the improvement of menstrual symptoms by the menstrual symptom reliever by comparing each answer of the first acquisition unit and the third acquisition unit acquired from a subject in whom the onset of premenstrual syndrome is recognized by the first determination unit; and an output unit that outputs the result determined by the second determination unit. A menstrual symptom improvement determination system is provided.

[0055] Conventionally, the answers of subjects for the evaluation of the menstrual symptom alleviation effect were often obtained on paper using a questionnaire. However, in the case of paper, since it is necessary to manage the answers by oneself, daily answers are essential to prevent forgetting to answer due to confusion about the answer date. In addition, since the menstrual cycle cannot be predicted, daily answers using a questionnaire were important.

[0056] On the other hand, according to the menstrual symptom improvement determination system, by using the second output unit that outputs at least one question regarding menstrual symptoms at least once from a certain period after the start of menstruation until a certain period, answer data can be obtained using a mechanism in which a questionnaire is automatically distributed every day from 6 days to 10 days after the start of menstruation. More specifically, by registering the start date of menstruation, answer data can be obtained using a mechanism in which a questionnaire is automatically distributed every day from 6 days to 10 days after the start of menstruation and from a certain period after the previous menstruation until the next menstruation.

[0057] For example, response data can be obtained by a smartphone, a personal computer, a tablet terminal, an application, or a web questionnaire. Therefore, the burden on the subject can be reduced.

[0058] The menstrual symptom improvement determination system according to a preferred example includes a first output unit that outputs questions regarding menstrual symptoms at least 3 days or more, preferably 5 days or more, from 15 to 18 days after the previous menstruation until the day before the next menstruation every month.

[0059] The menstrual symptom improvement determination system according to a preferred example includes a first acquisition unit that acquires responses before menstruation without smelling a menstrual symptom reliever for questions regarding menstrual symptoms.

[0060] The menstrual symptom improvement determination system according to a preferred example includes a second output unit that outputs questions regarding menstrual symptoms at least 3 days, preferably 5 days, after 6 days have passed since the start of menstruation every month.

[0061] The menstrual symptom improvement determination system according to a preferred example and a second acquisition unit that acquires responses after menstruation without smelling a menstrual symptom reliever for questions regarding menstrual symptoms.

[0062] The menstrual symptom improvement determination system according to a preferred example includes a third output unit that outputs questions regarding menstrual symptoms at least 3 days or more, preferably 5 days or more, from 15 to 18 days after the previous menstruation until the day before the next menstruation.

[0063] The menstrual symptom improvement determination system according to a preferred example includes a third acquisition unit that smells a menstrual symptom reliever and acquires responses before menstruation for questions regarding menstrual symptoms.

[0064] The menstrual symptom improvement determination system according to a preferred example includes a first determination unit that determines the presence or absence of the onset of premenstrual syndrome by comparing the response of the first acquisition unit with the response of the second acquisition unit.

[0065] The menstrual symptom improvement determination system according to a preferred example includes a second determination unit that determines the improvement of menstrual symptoms by the menstrual symptom reliever by comparing each answer of the first acquisition unit and the third acquisition unit, which is obtained from a subject in whom the onset of premenstrual syndrome is recognized by the first determination unit.

[0066] According to the menstrual symptom improvement determination system described above, the following advantages can be provided. · Since the answer date can be limited by predicting five days before the next menstruation from the previous menstruation, the burden of answering can be reduced. · Since the answer date can be confirmed, it becomes possible to determine whether the answers are submitted daily or in a lump, and the reliability of the data is improved. · Aggregation of answer results in real time becomes easy. · Since it can be distributed to a terminal that is always carried, the subject does not need to carry an answer sheet. Also, the subject can answer anywhere.

[0067] As described above, several embodiments have been explained, but each embodiment is presented as an example and does not limit the scope of the present invention. Each embodiment described in this specification can be variously modified within the range where the effects of the invention are achieved, and can be combined with the features described in other embodiments within the practicable range.

Example

[0068] Hereinafter, the present invention will be described in more detail using examples. However, the present invention is not limited to the description of the following examples.

[0069] [Example 1] As shown in Table 1 below, lavender-like fragrance 1 was formulated.

[0070]

Table 1

[0071] [Example 2] As shown in Table 2 below, lavender-like fragrance 2 was formulated.

[0072]

Table 2

[0073] [Example 3] As shown in Table 3 below, mint verbena-like fragrance was formulated.

[0074]

Table 3

[0075] [Example 4] As shown in Table 4 below, verbena-like fragrance was formulated.

[0076]

Table 4

[0077] [Preparation of Stick-shaped Menstrual Symptom Reliever] The stick-shaped menstrual symptom reliever 21 shown in Figure 1 was prepared. First, the components other than the fragrance in the raw materials of the oily solid 22 were mixed and then heated and melted. Thereafter, the fragrance of each example was added. After pouring the melt into a mold and cooling, the stick-shaped oily solid 21 was obtained. The stick-shaped menstrual symptom reliever 21 was obtained by mounting the oily solid 21 in a case 23 from which it could be drawn out. The preparation of the oily solid 21 and the production of the stick-shaped menstrual symptom reliever 21 were entrusted to a cosmetics manufacturer with which there was a business partnership.

[0078] [Selection of Subjects] Persons who met the following nine conditions were used as subjects. · Being a woman aged 20 - 45 years old. · Having had a menstrual period within the past year and having mental symptoms such as irritability and anxiety during the past year. · The degree of symptoms should fall into one of the five levels: "so troubled that unable to do any work, housework, study, etc.", "very troubled", "somewhat troubled", "not troubled", "no symptoms", specifically corresponding to either "very troubled" or "somewhat troubled". · The menstrual cycle is stable at around 25 - 35 days. · Not currently pregnant and having no recent plan to get pregnant. · Not taking medications or supplements for the purpose of improving premenstrual symptoms. However, taking analgesics is allowed. · Never been diagnosed with "depression" or "depressive state" from the past to the present. · Not under treatment in a psychiatric department or psychosomatic medicine department. · Having the intention to use stick perfume.

[0079] [Evaluation Method] Premenstrual symptoms were evaluated using the Japanese version of DRSP (Dairy Records of Severity of Problems). The details of the Japanese version of DRSP are as described in Takeda, T. et al. Int J Womens Health. 13, 361 - 367, 2021.

[0080] In this example, to reduce the burden on the subjects, the evaluation was conducted only during a certain period before and after menstruation. The response period of DRSP is shown in Table 5 and Figure 2.

[0081]

Table 5

[0082] As shown in Table 5 and Figure 2, in order to compare the DRSP scores during the sample non - use period and the use period, the samples were not used during the pre - menstrual periods of the first and second cycles, and the use of the samples was started from the pre - menstrual periods of the third and fourth cycles. In order to determine whether the subjects had pre - menstrual symptoms, the DRSP scores after the start of menstruation were also obtained. The pre - menstrual scores were obtained from the 18th day to the day before the start of menstruation, with the start of menstruation being the first day. After menstruation, scores for 5 days from the 6th day to the 10th day were obtained, with the start of menstruation being the first day.

[0083] DRSP consists of questions regarding 21 mental and physical symptoms and 3 social impairments. Each is evaluated on a 6 - point scale (0: no symptoms, 1: very mild, 2: mild, 3: moderate, 4: severe, 5: very severe). Each question is shown in Table 6. Each question was divided into 15 categories and analyzed separately. In Table 6, Mood represents mental symptoms, Physical represents physical symptoms, and Social is an indicator of the degree to which pre - menstrual symptoms affect social life. I represents depression, II represents anxiety, III represents emotional instability, IV represents anger, V represents decreased interest, VI represents decreased concentration, VII represents lethargy, VIII represents overeating and food preferences, IX represents sleep disorders, X represents a feeling of being overwhelmed, and XI represents physical symptoms.

[0084]

Table 6

[0085] For DRSP, the smartphone app "LINE" was used. Questions were distributed on the days when answers were required to obtain answers. Using the results of DRSP, comparisons were made between the sample use period and the non - use period, and the effects with and without Abies sachalinensis oil were compared.

[0086] [Method of using the sample] As samples, stick - shaped menstrual symptom relievers each containing the fragrance of each example were prepared. Subjects were asked to use each sample starting from the first day of the DRSP response in the third cycle. The use of samples during the DRSP response periods in the third and fourth cycles was mandatory, while the use in other periods was optional. The samples were used by directly applying them to any location (such as the inner wrist, neck muscle, chest, disposable mask, etc.) or by directly smelling the product. The number of uses per day was required to be about 4 times.

[0087] [Analysis method] Among the subjects, for the DRSP during the 5 days before menstruation (-5th day to -1st day) and the 5 days after menstruation (6th day to 10th day), those who answered for 4 days or more and did not take any medicine or supplements (except analgesics) during the test period were regarded as valid responders. Among the valid responders, those whose average value of the category to be investigated decreased by 30% or more after menstruation compared to before menstruation were judged to have premenstrual symptoms and were taken as the analysis subjects. More specifically, first, the alleviating effect of premenstrual symptoms was examined using the average value of each category.

[0088] For calculating the average value, the average value of 4 days or 5 days before and after menstruation was used. The average value of two cycles for each period was used. When the score value was 30% or more, it was judged to have premenstrual symptoms and was taken as the analysis subject. Among the analysis subjects, for the subjects who used the samples of Examples 1 to 4 and the subjects who did not use the samples, the score of each category was obtained. The P-value was calculated using the Wilcoxon signed-rank test, and the significance level was set at 5%.

[0089] [Results] The evaluation results of DRSP during the sample non-use period and the use period are shown in Figures 3 to 17. From the results shown in these figures, it was confirmed that a menstrual symptom reliever with an improved alleviating effect of menstrual symptoms can be provided. In particular, the stick-shaped menstrual symptom reliever is highly useful because it can be used easily and casually. Therefore, it is expected to contribute to the social spread of menstrual symptom relievers.

Industrial applicability

[0090] According to the present invention, there are provided a menstrual symptom reliever with improved menstrual symptom relief effect, a stick-shaped menstrual symptom reliever including the menstrual symptom reliever, and a method for relieving menstrual symptoms using the menstrual symptom reliever.

Explanation of Signs

[0091] 21 Stick-shaped menstrual symptom reliever 22 Oil-based solid agent 23 Case

Claims

1. A menstrual symptom relieving agent containing one or more members selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene and α-pinene.

2. A menstrual symptom relieving agent comprising one or more selected from the group consisting of linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimetol, nerolidol, camphor, α-isomethyl ionone, β-pinene, bornyl acetate, β-phellandrene, camphene, geraniol, citronellol, nerol, geranial, neral and γ-terpinene.

3. Linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimetol, nerolidol, borneol, camphor, α-isomethyl ionone, 3-pentyltetrahydro-2H-pyran-4-yl acetate, β- A menstrual symptom relieving agent comprising one or more selected from the group consisting of pinene, bornyl acetate, β-phellandrene, camphene, geraniol, citronellol, nerol, geranial, neral, γ-terpinene, ethylene brassylate, dihydromyrcenol, 3-methyl-5-phenylpentan-1-ol, 6,6-dimethoxy-2,5,5-trimethyl-2-hexene, citronellyl nitrile, benzyl alcohol, α-terpineol, γ-undecalactone, myrcene, geranyl acetate, γ-terpineol and methylheptenone.

4. The menstrual symptom relieving agent contains, as an active ingredient, one or more kinds selected from the group consisting of lavender-like fragrances, verbena-like fragrances and mint verbena-like fragrances.

5. The menstrual symptom relieving agent according to claim 4, wherein the lavender-like fragrance contains linalool, hexyl cinnamic aldehyde, linalyl acetate, limonene, α-pinene, tetrahydro-2-isobutyl-4-methylpyran-4-ol, galaxolide, methyl 2-hexyl-3-oxocyclopentanecarboxylate, 2-pentyl-2-cyclohexenone, 1-(2,3,8,8-tetramethyl-1,3,4,5,6,7-hexahydronaphthalen-2-yl)ethanone, coumarin, dimetol, nerolidol, borneol, camphor, bornyl acetate, 3-pentyltetrahydro-2H-pyran-4-yl acetate, β-phellandrene, β-pinene, camphene and α-isomethylionone.

6. 5. The menstrual symptom relieving agent according to claim 4, wherein the verbena-like fragrance contains hexyl cinnamic aldehyde, limonene, linalool, geraniol, citronellol, nerol, linalyl acetate, geranial, neral, citronellyl nitrile, benzyl alcohol, α-terpineol, β-pinene, γ-undecalactone, myrcene, γ-terpinene, geranyl acetate, γ-terpineol, methylheptenone, α-pinene, β-phellandrene, bornyl acetate and camphene.

7. 5. The menstrual symptom relieving agent according to claim 4, wherein the mint verbena-like fragrance contains hexyl cinnamic aldehyde, ethylene brassylate, tetrahydro-2-isobutyl-4-methylpyran-4-ol, linalool, limonene, dihydromyrcenol, geraniol, linalyl acetate, citronellol, nerol, geranial, β-pinene, galaxolide, β-phellandrene, neral, 3-methyl-5-phenylpentan-1-ol, bornyl acetate, camphene, α-pinene, 6,6-dimethoxy-2,5,5-trimethyl-2-hexene, and γ-terpinene.

8. The menstrual symptom relief agent according to claim 1, which is used for premenstrual symptoms.

9. The menstrual symptom relief agent according to claim 1, which is used for symptoms during menstruation.

10. 2. The menstrual symptom relieving agent according to claim 1, which is used for the purpose of relieving at least one of physical symptoms and mental symptoms.

11. The method for relieving menstrual symptoms according to claim 10, wherein the physical symptoms include at least one symptom selected from the group consisting of appetite disorders, sleep disorders, breast pain, breast swelling, bloating, weight gain, headache, joint pain and muscle pain.

12. The method for relieving menstrual symptoms according to claim 10, wherein the mental symptoms include at least one symptom selected from the group consisting of depression, anxiety, emotional instability, anger, lethargy, decreased concentration, and feeling overwhelmed.

13. Case and an oily solid agent contained in the case; Equipped with A stick-shaped menstrual symptom relief agent, comprising the oily solid preparation according to any one of claims 1 to 12.

14. A container; A fragrance contained in the container; Equipped with A fragrance-type menstrual symptom relief agent, comprising the menstrual symptom relief agent according to any one of claims 1 to 12.

15. A container; A bath additive contained in the container; Equipped with A bath additive-type menstrual symptom reliever comprising the menstrual symptom reliever according to any one of claims 1 to 12.

16. 1. A method for relieving menstrual symptoms, comprising: A method for relieving menstrual symptoms, comprising volatilizing the agent for relieving menstrual symptoms according to any one of claims 1 to 12.

17. 1. A method for relieving menstrual symptoms, comprising: A method for relieving menstrual symptoms, comprising inhaling the menstrual symptom relieving agent according to any one of claims 1 to 12.

18. 1. A method for relieving menstrual symptoms, comprising: A method for relieving menstrual symptoms, comprising continuously using the agent for relieving menstrual symptoms according to any one of claims 1 to 12 from 10 days before the onset of menstruation until during menstruation.

19. 1. A method for relieving menstrual symptoms, comprising: A method for relieving menstrual symptoms, comprising continuously using the agent for relieving menstrual symptoms according to any one of claims 1 to 12 from 5 days before the onset of menstruation until during menstruation.

20. 1. A method for relieving menstrual symptoms, comprising: A method for relieving menstrual symptoms, comprising using the menstrual symptom relieving agent according to any one of claims 1 to 12 when symptoms occur during menstruation.

21. A step 1 in which a subject obtains an evaluation (1) regarding menstrual symptoms before menstruation without smelling the menstrual symptom relieving agent according to any one of claims 1 to 12; A step 2 in which a subject obtains an evaluation (2) regarding menstrual symptoms after menstruation without smelling the menstrual symptom relieving agent according to any one of claims 1 to 12; A step 3 in which a subject sniffs the menstrual symptom relief agent according to any one of claims 1 to 12 before menstruation and obtains an evaluation regarding menstrual symptoms (3); a step 4 of determining whether or not premenstrual syndrome has developed by comparing the evaluation (1) obtained in the step 1 with the evaluation (2) obtained in the step 2; A step 5 of comparing the evaluation (1) and the evaluation (3) obtained from the subject who was found to have developed premenstrual syndrome in the step 4; A method for evaluating the effect of alleviating menstrual symptoms.

22. The evaluation method according to claim 21 , wherein in each of steps 1, 2, 3, 4, and 5, an evaluation is obtained before the onset of menstruation or on at least one day counting from the onset of menstruation.

23. a first output unit that outputs a question about menstrual symptoms at least once from a certain period after the previous menstruation until the next menstruation; a first acquisition unit that acquires a premenstrual answer to the question without smelling the menstrual symptom reliever according to any one of claims 1 to 12; a second output unit that outputs a question about menstrual symptoms at least once during a certain period of time after the start of menstruation; a second acquisition unit that acquires an answer to the question after the end of menstruation without smelling the menstrual symptom reliever according to any one of claims 1 to 12; a third output unit that outputs a question about menstrual symptoms at least once from a certain period after the last menstruation until the next menstruation; a third acquisition unit that acquires a response to the question before menstruation by sniffing the menstrual symptom alleviating agent according to any one of claims 1 to 12; a first determination unit that determines whether or not a premenstrual syndrome occurs by comparing a response from the first acquisition unit with a response from the second acquisition unit; a second determination unit that determines whether the menstrual symptom has been improved by the menstrual symptom-relieving agent by comparing the responses of the first and third acquisition units obtained from the subject who has been confirmed to have premenstrual syndrome by the first determination unit; an output unit that outputs a result determined by the second determination unit; A system for determining improvement of menstrual symptoms.

Images